dQ&A launched the beta of our next-gen AI Insights Platform—a breakthrough natural language solution providing instant, data-driven answers for the diabetes market.
dQ&A Presented Three Abstracts at EASD 2023 | dQ&A
New dQ&A data tracks GLP-1 & SGLT2 trends, patient/HCP insights, satisfaction, and market shifts to guide diabetes drug decisions.
We partnered with LMC to connect real-world patient experience insights with validated clinical data for patients across the diabetes spectrum.
A dQ&A-CeQur study in Clinical Diabetes finds 2 months on the CeQur Simplicity insulin patch boosts patient satisfaction, cuts burden, and lifts well-being.
This article reports results of a survey of patients and health care providers regarding their experiences of and challenges with the use of basal insulin.
Our research finds Mounjaro patients report health benefits but face confusion and frustration during therapy initiation.
We are excited to announce that the dQ&A team presented eight abstracts at the Advanced Technologies and Treatments for Diabetes (ATTD) 2023 conference.
dQ&A’s Trevor Bell publishes research in Current Diabetes Reports, offering insights into the critical role psychosocial issues play in diabetes management.
